Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this open label, interventional, randomized controlled clinical trial is to compare the efficacy and safety of ferric carboxymaltose injection with oral iron in treatment of postpartum iron deficiency anaemia in postnatal women. Inclusion criteria:women within 10 days of delivery, Hb >7 gm/dl and ≤10 gm and peripheral smear showing microcytic hypochromic anaemia or red cell indices suggestive of iron deficiency anaemia or Mentzer index >13.
Primary outcome measures-rise in Hb from baseline to 4 and 6 weeks Secondary outcome measures-Percentage of patients achieving Hb >11 g/dl at 4 and 6 weeks.
Percentage of patients achieving Hb rise >3 g/dl from baseline at 4 and 6 weeks Change in red cell indices and peripheral smear from baseline to 6 weeks Side effects profile of injectable Ferric carboxymaltose injection and oral iron.
Researcher compares the efficacy and safety of ferric carboxymaltose with Oral iron in post partum iron deficiency anaemia Participant's detailed history, general physical and systemic examination was performed. CBC with red cell indices, reticulocyte counts, peripheral smear examination, serum Iron, Ferritin, Transferrin, TIBC levels and LFT were done.
Subjects were randomized in a 1:1 ratio into two groups: Group I (n=100) received intravenous ferric carboxymaltose and Group II (n=100) received oral ferrous Fumarate twice a day for 6 weeks.
All subjects were followed at 4 and 6 weeks. Repeat Hb estimation was done at 4 and 6 weeks while RBC indices and serum iron parameters were repeated at 6 weeks. Adverse effects were recorded.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group I: Ferric carboxymaltose (FCM) | Experimental | FCM was given as slow intravenous infusion; maximum single dose not exceeding 15 mg/kg or 1000 mg/dose in 250 ml of 0.9% normal saline over 15 minutes During infusion, subject was kept under strict observation. FCM was repeated weekly up to calculated dose or maximum of 2500mg. Total dose of IV FCM was calculated by Ganzoni formula: - Total dose of iron = body weight (in kg) x (14-actual Hb) x 2.4 + 500 where, 14 is target Hb (g/dl), 2.4 unitless conversion constant, 500 is target iron store in mg |
|
| Group II : Oral Iron | Active Comparator | Second group of subjects were instructed to take oral iron (ferrous fumarate tablet containing 112 mg elemental iron) 2 times daily 1 hour before meals for 6 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ferric Carboxymaltose (FCM) | Drug | FCM was given as slow intravenous infusion; maximum single dose not exceeding 15 mg/kg or 1000 mg/dose in 250 ml of 0.9% normal saline over 15 minutes. FCM was repeated weekly up to calculated dose or maximum of 2500mg. |
| Measure | Description | Time Frame |
|---|---|---|
| Mean increase in haemoglobin at 4 weeks and 6 weeks in Group I versus Group II | The mean change in haemoglobin was measured at 4 weeks and 6 weeks post intervention in parenteral and oral group. | Haemoglobin measurement at baseline, 4 week post treatment and 6 week post FCM intervention or adequate oral treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Anaemia correction(Hb >11 gm/dl), from baseline at 4 and 6 weeks in group I versus Group II | Percentage of women in the parenteral group as compared to oral group who achieved correction of anaemia i.e. Hb >11gm/dl at 4 and 6 weeks post intervention. | Anaemia correction (Hb>11gm/dl) at 4 week and 6 week post FCM intervention or adequate oral treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Shreya Mahajan, MBBS | Post graduate resident, Department of OBG, ESI-PGIMSR, Basaidarapur,Delhi | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ESI-PGIMSR, Basaidarapur | Delhi | 110015 | India |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 13, 2026 | |
| Reset | Jul 9, 2026 |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Feb 23, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Haemoglobin (Hb) rise> 3gm/dl from baseline at 4 and 6 weeks in group I versus Group II | Women in the parenteral group as compared to oral group who achieved Haemoglobin rise of >3gm/dl at 4 and 6 weeks post intervention. | Hb rise> 3 gm/dl at 4 week and 6 week post FCM intervention or adequate oral treatment |
| Haemoglobin (Hb) rise>2gm from baseline at 4 and 6 weeks in group I versus Group II | Women in the parenteral group as compared to oral group who achieved haemoglobin (Hb) rise>2gm from baseline at 4 week and 6 week post intervention. | Hb rise>2gm/dl at 4 week and 6 week post FCM intervention or adequate oral treatment |
| Change in red cell indices and peripheral smear from baseline to 6 weeks | To record changes in all the haematological parameters from baseline to 6 weeks post intervention both parenteral and oral groups. | Change in red cell indices and peripheral smear at baseline and 6 week post FCM intervention or adequate oral treatment |
| Side effects profile for participants of Group I and II | To record the side effect profile in participants of parenteral and oral group in order to determine safety of the intervention upto 6 weeks post intervention. | Side effects observed in participants receiving Group I and Group II treatment upto 6 weeks post intervention.. |
| Jun 8, 2026 |
| Prot_SAP_ICF_000.pdf |
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 13, 2026 | Jul 9, 2026 |
| ID | Term |
|---|---|
| D000740 | Anemia |
| ID | Term |
|---|---|
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C522335 | ferric carboxymaltose |
Not provided
Not provided
Not provided